Abstract: The present invention provides a compound of chemical formula 1, a compound of chemical formula 3, compound [212], compound [224], or compound [228], a pharmaceutically acceptable salt thereof, a stereoisomer thereof, a hydrate thereof, or a solvate thereof, and a pharmaceutical composition comprising same. The pharmaceutical composition has excellent antiviral efficacy, thereby having a preventive or treatment effect on viral infectious disease such as SARS-COV-2, and exhibits an inhibitory effect on IL-5 expression and thus has a preventive or treatment effect on respiratory disease or allergic disease.

Abstract: A display device includes: a first pixel and a second pixel, including: a first transistor comprising a first active region, a first drain electrode, and a first source electrode respectively on one side and another side of the first active region, and a first gate electrode overlapping the first active region, a first capacitor electrode connected to the first gate electrode and overlapping the first source electrode, and a light emitting element connected to the first transistor, wherein a first end of the first source electrode of the first pixel, and a second end of the first source electrode of the second pixel face each other, a third end of the first capacitor electrode of the first pixel, and a fourth end of the first capacitor electrode of the second pixel face each other, and the first end is between the third end and the fourth end.

Abstract: The present disclosure relates to TM4SF5-specific humanized antibodies and uses thereof.

Abstract: The present disclosure relates to an organic electric element for realizing high luminous efficiency, and high heat resistance of the element, improve the color purity of the element, and increase the lifetime of the element.

Abstract: Disclosed is an image sensor including a plurality of column lines, a plurality of pixels coupled to the plurality of column lines, and configured to output a plurality of pixel signals to the plurality of column lines in response to first control signals, and a plurality of memory cells coupled to the plurality of column lines, and configured to output a plurality of convolution signals, in which a plurality of data signals are reflected in the plurality of pixel signals, to the plurality of column lines in response to second control signals.

Abstract: The present invention relates to a pharmaceutical composition comprising 1-(3-cyano-1-isopropyl-indol-5-yl)pyrazol-4-carboxylic acid or a pharmaceutically acceptable salt thereof, and a method of treating or inhibiting a hyperuricemia-related disease using the same, and the pharmaceutical composition of the present invention may effectively reduce the blood uric acid concentration in a patient with a hyperuricemia-related disease.

Abstract: A xylylene diisocyanate (XDI) composition according to exemplary embodiments includes xylylene diisocyanate and an acidity regulator having a boiling point of 110° C. or higher, and the composition has an acidity of greater than 100 ppm and 1,000 ppm or less based on a total weight of the xylylene diisocyanate (XDI). An optical lens having a high transmittance and improved optical uniformity can be manufactured by controlling a polymerization reaction rate through acidity adjustment.

Abstract: The present invention relates to a pharmaceutical composition comprising 1-(3-cyano-1-isopropyl-indol-5-yl)pyrazol-4-carboxylic acid or a pharmaceutically acceptable salt thereof, and a method of treating or inhibiting a hyperuricemia-related disease using the same, and the pharmaceutical composition of the present invention may effectively reduce the blood uric acid concentration in a patient with a hyperuricemia-related disease.

Abstract: Disclosed are mutated genes for green fluorescence proteins and enhanced inserted YFPs expressed therefrom. The mutant proteins not only maintain their fluorescence even at 37° C., but also exhibit about 20 times stronger fluorescence intensities in comparison to the conventional fluorescence proteins. Accordingly, the mutant fluorescence proteins of the present invention can be used as biosensors for detecting and analyzing the bioactivities of desired materials.

Abstract: Disclosed are mutated genes for green fluorescence proteins and enhanced inserted YFPs expressed therefrom. The mutant proteins not only maintain their fluorescence even at 37° C., but also exhibit about 20 times stronger fluorescence intensities in comparison to the conventional fluorescence proteins. Accordingly, the mutant fluorescence proteins of the present invention can be used as biosensors for detecting and analyzing the bioactivities of desired materials.